Navigation Links
UCL academics awarded prestigious prizes for work on the heart
Date:9/11/2008

Two UCL academics have received prominent international awards from the European Society of Cardiology (ESC), in recognition of their work to understand and treat conditions of the heart.

Professor John Martin, Director of the UCL Centre for Cardiovascular Biology & Medicine and British Heart Foundation Professor of Cardiovascular Science, has been awarded the ESC's Gold Medal. The only other holder of this medal in the UK is Sir James Black, Nobel Laureate. Dr Paul Riley, UCL Institute of Child Health, has been awarded the Outstanding Achievement Award 2008 of the ESC Council on Basic Cardiovascular Science.

Commenting on the ESC awards, Professor Ed Byrne, Executive Dean of the UCL Faculty of Biomedical Sciences and Head of the Medical School, said: "Heart and circulatory disease is the UK's biggest killer and these awards demonstrate that UCL research is breaking new ground in the understanding and treatment of these conditions. I am delighted that the ESC has chosen to recognise the scientific endeavours of John and Paul and offer my sincere congratulations to them both."

Professor Martin has pursued an active research career, examining how the manufacture of platelets in the body causes blood to clot, how arteries age, and the protective role played by the gene for vascular endothelial growth factor (VEGF). His realisation that VEGF could be used therapeutically led him to start his own company, Ark Therapeutics, which is now taking gene therapy for vascular damage through clinical trials. He has also begun a phase III clinical trial to test whether the damage of heart attack can be repaired by direct injection of a patient's own bone marrow cells into the heart muscle.

Professor Martin also wrote the Heart Plan for Europe, a 'tool box' to help each country design its own bespoke prevention package for heart health, and he serves on a number of professional boards. As well as his scientific and medical endeavours, Professor Martin is a published writer and poet. He studied for his first degree in philosophy at a Spanish University and is fluent in Spanish and French, as well as being a keen artist.

The award made to Dr Paul Riley, Reader in the Molecular Medicine Unit at the UCL Institute of Child Health, recognises a landmark discovery in the field of basic cardiovascular science when his team found that a protein called Thymosin beta4 could mobilise dormant cells from the epicardium to form new blood vessels in the heart a major step towards finding a DIY mechanism to repair injury following heart attack.

Dr Riley said: "I'm very pleased indeed that my work has attracted professional recognition from the ESC." When not engaged in scientific pursuits, Dr Riley is a keen footballer, playing in an 8-a-side league with other scientists and clinicians close to the Institute in nearby Coram's Fields.


'/>"/>

Contact: Ruth Metcalfe
r.metcalfe@ucl.ac.uk
44-076-799-739
University College London
Source:Eurekalert

Related medicine news :

1. SpectraScience Awarded Patent for Correcting Image Misalignment
2. Phoenix Health Systems Awarded Level 2 Carnegie Mellon University eSCM-SP Certification
3. ACS Awarded $4 Million Contract to Provide Electronic Patient Records for City of New Orleans EMS
4. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
5. Canica Design Awarded Milestone U.S. Patent for Dynamic Wound Closure Systems
6. Availity Awarded Full EHNAC Accreditation
7. All-Med Services of Florida Awarded Medicare Competitive Bidding Contract
8. Nyer Medical Group, Inc. Announces Sale of Companys Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract
9. TruFUSE(R) Patents Awarded
10. Pioneering stroke researcher awarded Canadas highest honor
11. Pathway Medical Technologies Awarded New Patent for Pathway PV(TM) Atherectomy System for Improved Differential Cutting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: